Metastatic breast cancer trials in Belgium

In Belgium 34 Also abroad 610

34 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Where
Brussels, Edegem, Leuven, Libramont-Chevigny, Liège, Namur
Age
18 years and over
People
910 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06324357
Phase 3Taking people
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Where
Anderlecht, Edegem, Gent, Jette, Leuven, Libramont-Chevigny, Liège, Namur, Sint-Lambrechts-Woluwe, Sint-Niklaas, Verviers
Age
18 years and over
People
540 worldwide
Run by
Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00
Phase 2/3Taking people
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Where
Anderlecht, Brussels, Hasselt, Kortrijk, Leuven, Mechelen, Namur, Wilrijk
Age
18 years and over
People
650 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00
Phase 3Taking people
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Where
Anderlecht, Hasselt, Kortrijk, Leuven, Namur, Ottignies, Sint-Niklaas
Age
18 years and over
People
800 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00
Phase 2Taking people
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Where
Hasselt, Leuven, Namur, Sint-Lambrechts-Woluwe
Age
18 years and over
People
80 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07368998 · EU 2025-522805-39-00
Phase 3Taking people
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
Where
Anderlecht, Charleroi, Edegem, Namur, Roeselare
Age
18 years and over
People
264 worldwide
Run by
Jazz Pharmaceuticals Ireland Limited
See details and how to joinNCT06435429 · EU 2023-508960-31-00
Phase 3Taking people
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Where
Leuven, Namur, Sint-Lambrechts-Woluwe
Age
18 years and over
People
600 worldwide
Run by
LeonaBio
See details and how to joinNCT05696626 · EU 2023-503708-10-00
Phase 2Taking people
HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
Where
Aalst, Anderlecht, Brussels, Jette, Leuven, Sint-Lambrechts-Woluwe
Age
18 years and over
People
60 worldwide
Run by
Abscint NV/SA
See details and how to joinNCT06369831 · EU 2024-511419-22-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Where
Charleroi, Edegem, Gent, Leuven, Namur, Sint-Lambrechts-Woluwe
Age
18 years and over
People
420 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05646862 · EU 2022-502322-41-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Charleroi, Gent, Leuven, Liège, Sint-Lambrechts-Woluwe
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1Not yet taking people in Belgium
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Sint-Lambrechts-Woluwe
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Where
Anderlecht, Brasschaat, Charleroi, Edegem, Hasselt, Leuven, Liège, Ottignies-Louvain-la-Neuve, Sint-Lambrechts-Woluwe, West-Vlaanderen
Age
18 years and over
People
400 worldwide
Run by
Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Where
Anderlecht, Brasschaat, Brussels, Charleroi, Gent, Hasselt, Jette, La Louvière, Liège, Mons, Namur, Sint-Lambrechts-Woluwe, Verviers
Age
18 years and over
People
230 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00
Phase 3Taking people
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Where
Anderlecht, Brussels, Ghent, Hasselt, Namur
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00
Phase 3Taking people
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Where
Charleroi, Gent, Hasselt, Leuven, Sint-Lambrechts-Woluwe
Age
18 years and over
People
1,180 worldwide
Run by
Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01
Phase 1/2Taking people
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Where
Brussels, Leuven
Age
18 years and over
People
220 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07701941 · EU 2024-517541-14-00
Phase 3Taking people
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Where
Charleroi, Jette, Kortrijk, Liège, Sint-Lambrechts-Woluwe
Age
18 years and over
People
1,000 worldwide
Run by
Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00
No phaseTaking people
EORTC Metastatic Breast Cancer Module Development
Where
Ghent
Age
18 years and over
People
568 worldwide
Run by
University of Leeds
See details and how to joinNCT07806266
Phase 1Taking people
A First-in-Human phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-271 in tumors and critical organs in subjects with HER2-positive metastatic breast cancer
Where
Anderlecht
Age
18 years and over
People
30 worldwide
Run by
Affibody AB
See details and how to join2024-518360-13-00 · EU 2024-518360-13-00
Phase 2Taking people
LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor
Where
Anderlecht, Edegem, Leuven, Liège
Age
18 years and over
People
36 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT04939610 · EU 2023-508995-12-01
Phase 3Taking people
A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in patients with HR+/HER2- advanced breast cancer and disease progression despite prior hormone-based treatment (CAPIcorn)
Where
Anderlecht, Antwerp, Bruxelles-Capitale, Namur
Age
18 years and over
People
250 worldwide
Run by
WSG Women's Cancer Study Group GmbH
See details and how to join2024-511392-15-00 · EU 2024-511392-15-00
No phaseTaking people
DESTINY Breast Respond HER2-(Ultra)Low Europe
Where
Aalst, Auderghem, Bonheiden, Brasschaat, Bruges, Brussels, Haine-Saint-Paul, Hasselt, La Louvière, Liège, Namur, Ottignies, Sint-Niklaas, Verviers
Age
18 years and over
People
2,295 worldwide
Run by
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
See details and how to joinNCT05945732
Phase 1/2Taking people
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Where
Anderlecht, Leuven
Age
18 years and over
People
270 worldwide
Run by
Lumara Bio Oncologics GmbH
See details and how to joinNCT05706129 · EU 2023-504254-35-00
No phaseTaking people
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
Where
Brussels, Charleroi, Leuven, Liège, Namur
Age
18 years and over
People
1,000 worldwide
Run by
Jules Bordet Institute
See details and how to joinNCT02102165
Phase 3Taking people
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
Where
Anderlecht
Age
18 years and over
People
250 worldwide
Run by
Women's Cancer Study Group GmbH
See details and how to joinNCT07281833